Premium
Front‐line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group
Author(s) -
Luksch Roberto,
Grignani Giovanni,
D'Angelo Paolo,
Prete Arcangelo,
Puma Nadia,
Podda Marta,
Casanova Michela,
Ferrari Andrea,
Morosi Carlo,
Fagioli Franca,
Aglietta Massimo,
Ferrari Stefano,
Picci Piero,
Massimino Maura
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26650
Subject(s) - medicine , sarcoma , cisplatin , front line , soft tissue sarcoma , stage (stratigraphy) , oncology , chemotherapy , surgery , pathology , paleontology , biology , political science , law
Abstract The aim was to assess the activity of cisplatin (CDDP) in Ewing sarcoma (ES). The study consisted of front‐line window therapy with CDDP 120 mg/sqm every 3 weeks for two courses in children and young adults with primary disseminated ES. Response was assessed using the Response Evaluation Criteria in Solid Tumours criteria, and Simon's two‐stage design was applied. Twelve consecutive patients were enrolled in stage 1. Only one objective response was observed. Since the target response rate was not achieved, accrual was stopped and CDDP as a single agent in ES was judged unworthy of further assessment.